Katherine Bell-McGuinn, M.D., Ph.D., joins as chief medical officer Company expects to initiate a Phase I clinical trial of its PARG inhibitor ETX-19477 in 2024 SAN DIEGO (BUSINESS WIRE) 858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical.